DK1855711T3 - Anvendelse af BAFF til behandling af Th2-medierede tilstande - Google Patents

Anvendelse af BAFF til behandling af Th2-medierede tilstande

Info

Publication number
DK1855711T3
DK1855711T3 DK06734022T DK06734022T DK1855711T3 DK 1855711 T3 DK1855711 T3 DK 1855711T3 DK 06734022 T DK06734022 T DK 06734022T DK 06734022 T DK06734022 T DK 06734022T DK 1855711 T3 DK1855711 T3 DK 1855711T3
Authority
DK
Denmark
Prior art keywords
baff
treat
mediated conditions
mediated
conditions
Prior art date
Application number
DK06734022T
Other languages
English (en)
Inventor
Charles Mackay
Fabienne Mackay
Susan Kalled
Original Assignee
Biogen Idec Inc
Garvan Inst Med Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Garvan Inst Med Res filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK1855711T3 publication Critical patent/DK1855711T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK06734022T 2005-01-28 2006-01-27 Anvendelse af BAFF til behandling af Th2-medierede tilstande DK1855711T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64809805P 2005-01-28 2005-01-28
PCT/US2006/003127 WO2006081516A2 (en) 2005-01-28 2006-01-27 USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS

Publications (1)

Publication Number Publication Date
DK1855711T3 true DK1855711T3 (da) 2009-10-12

Family

ID=36741125

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06734022T DK1855711T3 (da) 2005-01-28 2006-01-27 Anvendelse af BAFF til behandling af Th2-medierede tilstande

Country Status (9)

Country Link
US (1) US20080254030A1 (da)
EP (1) EP1855711B1 (da)
AU (1) AU2006209237B2 (da)
CA (1) CA2596276A1 (da)
DE (1) DE602006007323D1 (da)
DK (1) DK1855711T3 (da)
HK (1) HK1110803A1 (da)
NZ (1) NZ560285A (da)
WO (1) WO2006081516A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
WO2002016411A2 (en) * 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
EA015860B1 (ru) * 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
US8211649B2 (en) * 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
EP2396035A4 (en) * 2009-02-12 2012-09-12 Human Genome Sciences Inc USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
US8735347B2 (en) 2011-02-02 2014-05-27 Children's Hospital Medical Center Regulation of energy metabolism and obesity by modulating B cell activating factor (BAFF, BLYS) or BAFF signaling

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6541224B2 (en) * 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US20030175208A1 (en) * 1996-10-25 2003-09-18 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6689579B1 (en) * 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US20030022239A1 (en) * 1997-06-18 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20020055624A1 (en) * 1997-11-17 2002-05-09 Steven R. Wiley Tnf-delta ligand and uses thereof
US20010010925A1 (en) * 1997-11-17 2001-08-02 Steven R. Wiley Methods of detecting target nucleic acids of tnf-delta
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
US20030095967A1 (en) * 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
DE60004635T2 (de) * 1999-01-25 2004-06-09 Biogen, Inc., Cambridge Baff, dessen inhibitoren und dessen verwendung zur modulierung der b-zell-antwort
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
US6475987B1 (en) * 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
BRPI0013391B8 (pt) * 1999-08-17 2021-05-25 Apotech R&D S A uso de polipeptídeos bcma na preparação de uma composição farmacêutica para tratar uma doença autoimune ou um distúrbio linfoproliferativo de célula b
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
JP2003521931A (ja) * 2000-02-11 2003-07-22 バイオジェン インコーポレイテッド Ｔｎｆファミリーの異種ポリペプチド
US20040013674A1 (en) * 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
WO2002002641A1 (en) * 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US6475686B2 (en) * 2000-07-28 2002-11-05 Canon Kabushiki Kaisha Fixing method
WO2002016411A2 (en) * 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
US7238499B2 (en) * 2001-12-21 2007-07-03 Immunex Corporation Trimeric macrophage scavenger receptor fusion proteins and encoding nucleic acids
US20030211509A1 (en) * 2002-03-26 2003-11-13 Wiley Steven R. TNF-delta ligand and uses thereof

Also Published As

Publication number Publication date
HK1110803A1 (en) 2008-07-25
DE602006007323D1 (de) 2009-07-30
EP1855711A2 (en) 2007-11-21
WO2006081516A2 (en) 2006-08-03
EP1855711B1 (en) 2009-06-17
AU2006209237B2 (en) 2010-06-24
WO2006081516A3 (en) 2007-05-03
CA2596276A1 (en) 2006-08-03
US20080254030A1 (en) 2008-10-16
NZ560285A (en) 2011-04-29
AU2006209237A1 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
DK1855711T3 (da) Anvendelse af BAFF til behandling af Th2-medierede tilstande
DK1720866T3 (da) Fremgangsmåde
DK2500017T3 (da) Anvendelse af ketogene forbindelser til behandling af aldersrelateret hukommelsessvækkelse
DK1942938T3 (da) Anvendelse af oligouronater til behandling af slim-hyperviskositet
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
BRPI0811473A2 (pt) Compostos hidrossolúveis de magnésio como agentes de limpeza e métodos de utilização dos mesmos.
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
DK1874821T3 (da) Kombination af antistoffer med glykokortikoider til behandling af kræft
DK2329012T3 (da) Behandling af slagtilfælde under anvendelse af isolerede placentaceller
BRPI0914682A2 (pt) compostos de heteroarila e usos dos mesmos
FR2896407B3 (fr) Ambulateur
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
ATE476424T1 (de) Diazepanderivate als modulatoren von chemokinrezeptoren
DK2211846T3 (da) Hidtil ukendte tilgange til behandling af CMT- og beslÇgtede lidelser
DE112007000789A5 (de) Verwendung von Bora-tetraazepentalenen
DE602005023266D1 (de) Azabenzofuransubstituierte thioharnstoffe als inhibitoren der virusreplikation
BRPI0817267A2 (pt) Prevenção de alergia em desmame
DK2373927T3 (da) Behandling af forbrændingsgas fra affaldsbehandling
BRPI0915394A2 (pt) purificação de citoquinas modificadas
DK2111555T3 (da) Diagnosticering af præeklampsi
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
BRPI0813830A2 (pt) Purificação de polipeptídeos peguilados
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
FI20065834A0 (fi) Iskulaite
BRPI0715728A8 (pt) tratamento de distúrbios cartilaginosos